CoChat
Sign Up
Cited by 184Folate and B Vitamins ResearchColorectal Cancer Treatments and StudiesCancer therapeutics and mechanisms

The DOI matches its Crossref record; 352 of the 353 references it cites were found in a registry or an index.

From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates

Walling, Jackie·2006·Investigational New Drugs
DOI 10.1007/s10637-005-4541-1
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1007/s10637-005-4541-1

Cites

352 of 352 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

1 of the 353 references couldn’t be matched to a known paper.

Research works printed but not linked: 25

  1. Li MC, Hertz R, Spence DB: Effect of methotrexate therapy on choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med 93:Abstract 361, 1956 · DOI
  2. Allegra CJ: In: Chabner BA, Collins JM (eds) Antifolates in Cancer Chemotherapy Principles and Practice. Lippincott, 1990, pp. 110–152
  3. Ross JF, Chaudhuri PK, Ratnam M: Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Cancer Res 73:2432–2434, 1994
  4. Bruckner HW, Lokich JJ, Stablein DM: Studies of Bakers antifol, methotrexate and razozane in advanced gastric cancer: A Gastrointestinal Tumour study group report. Cancer Treat Rep 66:1713–1717, 1982
  5. Gesme DH Jr, Jett JR, Schreffler DD, Su JQ, Maillard JA, Foley JF, KrookJE, Maksymiuk AW, Hatfield AK, Ebbert LP: A randomized phase II trial of amonafide or Trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group. Cancer 71(9):2723–2726, 1993
  6. Blanke CD, Kasimis B, Schein P. Capizzi R, Kurman M: Phase II study of trimetrexate, fluorouracil and leucovorin for advanced colorectal cancer. J Clin Oncol 15:915–920, 1997 · DOI
  7. Casper ES, Christman KL, Schwartz GK, Johnson B, Brennan MF, Bertino JR: Edatrexate in patients with soft tissue sarcoma. Activity in malignant fibrous histiocytoma. Cancer 72(3):766–770, 1993
  8. Schornagel JH, Verweij J, de Mulder PH, Cognetti F, Vermorken JB, Cappelaere P, Armand JP, Wildiers J, de Graeff A, Clavel M: Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: A European Organization for Research and Treatment of Cancer Head and Neck Cooperative Group study. J Clin Oncol 13(7):1649–1655, 1995 · DOI
  9. Gralla RJ, Lee JS, Kris MG, Comis RL, Sridhar KS, Crawford J, Hirsh V, Wernz JC, Belani CP, Vokes E: Multicenter, randomized trial comparing the combination of edatrexate, mitomycin and vinblastine (EMV) with mitomycin and vinblastine (MV) in 673 patients with stage III and IV non-small cell lung cancer. Abstract. Proc Am Soc Clin Oncol 13:1161, 1994
  10. Pazdur R, Vincent M: Raltitrexed (Tomudex) versus 5 fluorouracil and leucovorin (5FU +LV) in patients with advanced colorectal cancer (ACC): Results of a randomized, multicenter, North American Trial. Abstract. Proc Am Soc Clin Oncol 16:801, 1997
  11. Douillard J, Michel P, Gamelin E, Conroy T, Francois E, Raoul J, Becouarn Y, Bertheault F Cvitkovic S, Nasca S, Ychou M, Fandi A, Seitz J: Raltitrexed (Tomudex) plus oxaliplatin: An active combination for first line chemotherapy in patients with metastatic colorectal cancer. Abstract. Proc Am Soc Clin Oncol 19:971, 2000
  12. Van Laethem JL, Van Maele Ph, Polus M, Demols A, Houbiers Gh, Leleux A, Schurmans P, D'Haens G, Recloux P, Caenepeel P, Ryssaert T, Daems K, Verslype C, Van Cutsem E, Peeters M: Raltitrexed (Tomudex) and gemcitabine (Gemzar) in advanced pancreatic carcinoma: A Belgian multicenter phase II study. Abstract. Proc Am Soc Clin Oncol 21:547, 2002
  13. Decreux M, Fizazi K, Daniel C, Ruffie P, Kabouche A, Fandi A, Smith M, Armand JP: Updated results of a phase I trial of tomudex (T) in combination with oxaliplatin (L-OHP) in advanced solid tumors: A promising and active combination. Abstract. Ann Oncol 9 (suppl 4):6020, 1998
  14. Mani S, Rosen L, Bennet P, Dancey J, Conner S, Johnston A, Clendeninn N: A phase II trial of nolatrexed dihydrochloride (Thymitaq, AG337) in patients with advanced hepatocellular carcinoma. Abstract. In: Proc 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy: 1998, p 619
  15. Grindey GB, Alati T, Lantz R, Pohland R, Shih C: Role of dietary folic acid in blocking the toxicity but not the antitumor activity of lometrexol. Abstract. In: Proc Am Assoc Can Res 32:1921, 1991
  16. Grindey GB, Alati T, Lantz R, Pohland R, Shih C: Role of dietary folic acid in blocking the toxicity but not the antitumor activity of lometrexol (DDATHF). Abstract. In: Proc NCI-EORTC Symposium on New Drugs in Cancer Therapy: 1992, p 216
  17. Wedge SR, Laohavinij S, Taylor GA, Boddy A, Calvert AH, Newell DR: Clinical pharmacokinetics of the antipurine antifolate (6R) -5, 10-dideazatetrahydrofolic acid (lometrexol) administered with an oral folic acid supplement. Clin Cancer Res 1:1479–1486, 1995
  18. Nelson R, Butler F, Dugan W Jr, Davis-Land M, Stone M, Dyke R: Phase I clinical trial of LY 264618 (Dideazatetrahydrofolic acid: DDATHF). Abstract. In: Proc Am Soc Clin Oncol 9:76, 1990
  19. Ayelsworth C, Baker SD, Stephenson J, Monroe P, Sanchez I, Walling J, Johnson R, Von Hoff D, Rowinsky E: Phase I and pharmacokinetic (pk) study of the glycinamide ribonucleotide formyltransferase (GARFT) inhibitor LY309887 as a bolus every 3 weeks with folic acid (FA). Abstract. In: Proc Am Soc Clin Oncol 17:865, 1998
  20. Halford S, Harper P, Highley M, Lind M, Calvert AH, Johnson R, Walling J: A Phase I and pharmacokinetic study of LY309887 given ever 3 weeks with folic acid supplementation. Abstract. In: Proc Am Soc Clin Oncol 18:652, 1999
  21. Kindler H, Dugan W, Hochster H, Strickland D, Jacobs A, John W J. Clinical outcome in patients (pts) with advanced pancreatic cancer treated with pemetrexed/gemcitabine. Abstract. In: Proc Am Soc Clin Oncol 21:499, 2002
  22. Atkins JN, Jacobs S, Wieand S, Smith R, John W, Renshaw G, Colangelo L., Geyer C Jr., Wolmark N: Pemetrexed and oxaliplatin for first line treatment of patients with advanced colorectal cancer: A phase II trial of the NSABP foundation research program. Abstract. Proc Am Soc Clin Oncol 22:1108, 2003
  23. Paz Ares L, Tabemoro J, Moyano A, Rifa J, Alonso J, Marcuello E, Gonzalez A, Castellano D, Hermandez S, Cotes-Funes H, Doce H: Significant activity of the multitargeted antifolate MTA (LY231514) in advanced transitional cell carcinoma (TCC) of the bladder: Results of a phase II trial. Abstract. Ann Oncol 9 (suppl 4):291, 1998
  24. Goedhals L, van Wijk AL: MTA (LY231514) in advanced carcinoma of the cervix. Abstract. Ann Oncol 9 (suppl 4):339P, 1998
  25. Vogelzang NJ, Emri S, Boyer MJ, Gatzemeier U, Jablons D, Taub R, Paul S, Shah P, Nguyen B: Effect of folic acid and vitamin b12 supplementation on risk benefit ratio from phase III study of pemetrexed + cisplatin versus cisplatin in malignant pleural mesothelioma. Abstract. In: Proc Am Soc Clin Oncol 22:2644, 2003

Cited by

Sorted by citations

See all 184

Related

See all

Metadata

Authors
Walling, J.
Affiliations
University of Bristol (GB)
Corresponding author
Walling, Jackie
ORCID
Walling, Jackie
Venue
Investigational New Drugs
Publisher
Springer Science and Business Media LLC
Published
2006-01
Volume
24
Issue
1
Pages
37-77
ISSN
  • 0167-6997 (ISSN-L)
  • 1573-0646
DOI
10.1007/s10637-005-4541-1
OpenAlex
W1993777583
Cited by
182
References
353
Citations by year
2026: 4 · 2025: 7 · 2024: 9 · 2023: 4 · 2022: 11 · 2021: 15 · 2020: 12 · 2019: 10 · 2018: 7 · 2017: 7 · 2016: 8 · 2015: 17 · 2014: 9 · 2013: 7 · 2012: 8
FWCI
1.55
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Investigational New Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Folate and B Vitamins Research
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords
antifolate, methotrexate, pemetrexed, pharmacodynamics, clinical properties
MeSH terms
Pemetrexed, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Biological Transport, Folic Acid Antagonists, Glutamates, Guanine, Humans, Methotrexate, Neoplasms, Randomized Controlled Trials as Topic, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review